On September 27-29, 2022 in Boston, MA, Dr. Dan Benjamin will be speaking at the 6th annual Complement-based Drug Development Summit, www.complement-therapeutics.com.
The title of the talk is:Targeted Delivery Platform of sC3, a Complement Depleting Protein, Using Viral Delivery, Conjugate Guidance, & Localized Application Modalities
Topics:
• Discover how specific cell types in the retina and kidney can be targeted to express sC3
• Conjugate guidance and tissue specific local delivery are being developed to increase efficacy and decrease off target effects
• Taken together, these technologies allow Cascade to optimize treatment based on the therapeutic target
Please contact Dr. Benjamin on this website or at: daniel.benjamin@cascadebiotechnology.com
Disease Program | Research Project Codes | Project Phase | Status |
Amyotrophic Lateral Sclerosis | CB901 | Early Discovery | In Vitro Research |
*links to detailed page |
Vogel CW, Fritzinger DC, Gorsuch WB et al. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases. Thromb Haemost 2015;113:548-52
Vogel CW, Finnegan PW, Fritzinger DC. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models. Mol Immunol 2014;61:191-203
Huda R, Fritzinger DC, Finnegan PF, et al. Complement depletion with humanized Cobra Venom Factor (CVF) improves the severity of Experimental Autoimmune Myasthenia Gravis (EAMG). Mol Immunol 2011;48:1712
Fritzinger DC, Dean R, Meschter C, et al. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Adv Exp Med Biol 2010;703:151-62
Fritzinger DC, Damaj BB, Wong K, et al. Pharmacokinetics of humanized cobra venom factor in mice. Mol Immunol 2010;47:2268-2269
Vogel C-W, Fritzinger DC. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 2010;56:1198-1222
Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009;114:5322-30
Gorsuch WB, Guikema BJ, Fritzinger DC, et al. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Mol Immunol 2009;47:506-10
Fritzinger DC, Hew BE, Thorne M, et al. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Dev Comp Immunol 2009;33:105–116
Fritzinger DC, Ferreira VP, Hew BE, et al. A novel concept for the treatment of paroxysmal nocturnal haemoglobinuria (PNH): complement depletion with a human C3 derivative with cobra venom factor-like activity prevents lysis of PNH erythrocytes. Mol Immunol 2008;45:4177
Fritzinger DC, Hew BE, Lee JQ, et al. Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: in vivo activity and lack of toxicity in primates. Mol Immunol 2008;45:4112
Fritzinger DC, Hew BE, Lee JQ, et al. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Adv Exp Med Biol 2008;632:293-307
Vogel CW, Fritzinger DC. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Curr Pharm Des 2007;13:2916-26
Fritzinger DC. Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents. Hawaii Med J 2005;64:133-4, 137
Fritzinger DC, Benjamin DE. The Complement System in Neuropathic and Postoperative Pain. Open Pain J. 2016 ; 9: 26–37
Brucato FH, Benjamin DE. Synaptic Pruning in Alzheimer's Disease:Role of the Complement System. Global Journal of Medical Research F:Diseases 2020;Volume 20 Issue 6 Version1.0. ISSN: 2249-4618 & Print ISSN:0975-5888
NIH Funding
Grant Number: 1 R43 HL139170-01A1Principal Investigator: Fritzinger, David Charles Project Title: Preparation and development of a stabilized C3 analog for the treatment of paroxysmal nocturnal hemoglobinemia Institution: CASCADE BIOTECHNOLOGY Award Issue Date: 09/21/2018
Professor University of Miami Miller School of Medicine
www.scripps.edu/florida/neuro/cwahlestedt.html
Chief Scientific Officer, Cue Biopharma
https://be.linkedin.com/in/anishsuri
Daniel E. Benjamin Ph.D. is the Chief Executive Officer (CEO) of our company. With his extensive knowledge and experience, he leads the organization in setting strategic goals and implementing effective business strategies. He oversees the overall operations of the company, including financial performance, resource allocation, and risk management. Under his leadership, the company has achieved significant growth and success.
T
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020). Complement in neurological disorders and emerging complement-targeted therapeutics. In Nature Reviews Neurology (Vol. 16, Issue 11, pp. 601–617). Nature Research. https://doi.org/10.1038/s41582-020-0400-0
Goetzl, E. J., Srihari, V. H., Guloksuz, S., Ferrara, M., Tek, C., & Heninger, G. R. (2020). Decreased mitochondrial electron transport proteins and increased complement mediators in plasma neural-derived exosomes of early psychosis. Translational Psychiatry 10 (1). https://doi.org/10.1038/s41398-020-01046-3
Kamitaki, N., Sekar, A., Handsaker, R. E., de Rivera, H., Tooley, K., Morris, D. L., Taylor, K. E., Whelan, C. W., Tombleson, P., Loohuis, L. M. O., Ripke, S., Neale, B. M., Corvin, A., Walters, J. T. R., Farh, K. H., Holmans, P. A., Lee, P., Bulik-Sullivan, B., Collier, D. A., … Spencer, C. C. A. (2020). Complement genes contribute sex-biased vulnerability in diverse disorders. Nature https://doi.org/10.1038/s41586-020-2277
Kopczynska, M., Zelek, W., Touchard, S., Gaughran, F., Di Forti, M., Mondelli, V., Murray, R., O’Donovan, M. C., Morgan, B. P. (2019). Complement system biomarkers in first episode psychosis. Schizophrenia Research 204,16–22. https://doi.org/10.1016/j.schres.2017.12.012
Magdalon, J., Mansur, F., Teles e Silva, A. L., de Goes, V. A., Reiner, O., Sertié, A. L. (2020). Complement System in Brain Architecture and Neurodevelopmental Disorders. In Frontiers in Neuroscience (Vol. 14). Frontiers Media S.A. https://doi.org/10.3389/fnins.2020.00023
Mongan, D., Sabherwal, S., Susai, S. R., Föcking, M., Cannon, M., Cotter, D. R. (2020). Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies. In Schizophrenia Research (Vol. 222, pp. 58–72). Elsevier B.V. https://doi.org/10.1016/j.schres.2020.05.036
Purves-Tyson, T. D., Robinson, K., Brown, A. M., Boerrigter, D., Cai, H. Q., Weissleder, C., Owens, S. J., Rothmond, D. A., & Shannon Weickert, C. (2020). Increased Macrophages and C1qA, C3, C4 Transcripts in the Midbrain of People With Schizophrenia. Frontiers in Immunology 11 https://doi.org/10.3389/fimmu.2020.02002
Sellgren, C. M., Gracias, J., Watmuff, B., Biag, J. D., Thanos, J. M., Whittredge, P. B., Fu, T., Worringer, K., Brown, H. E., Wang, J., Kaykas, A., Karmacharya, R., Goold, C. P., Sheridan, S. D. Perlis, R. H. (2019). Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nature Neuroscience 22 (3), 374–385. https://doi.org/10.1038/s41593-018-0334-7
Wallace, J., Lord, J., Dissing-Olesen, L., Stevens, B., Murthy, V. N. (2020). Microglial depletion disrupts normal functional development of adult-born neurons in the olfactory bulb. ELife. https://doi.org/10.7554/eLife.50531
Woo, J. J., Pouget, J. G., Zai, C. C., Kennedy, J. L. (2020). The complement system in schizophrenia: where are we now and what’s next? In Molecular Psychiatry (Vol. 25, Issue 1, pp. 114–130). Springer Nature. https://doi.org/10.1038/s41380-019-0479-0